P
Paul J. Perry
Researcher at Touro University California
Publications - 182
Citations - 9133
Paul J. Perry is an academic researcher from Touro University California. The author has contributed to research in topics: Olanzapine & Atypical antipsychotic. The author has an hindex of 51, co-authored 182 publications receiving 8664 citations. Previous affiliations of Paul J. Perry include University of Iowa Hospitals and Clinics & Roy J. and Lucille A. Carver College of Medicine.
Papers
More filters
Journal ArticleDOI
The Anticholinergic Drug Scale as a Measure of Drug-Related Anticholinergic Burden: Associations With Serum Anticholinergic Activity
TL;DR: This study replicated findings on the association of the ADS with SAA and determined whether the ADS is clinically useful for preventing anticholinergic adverse effects, and examined modifications that did not appear useful in optimizing the ADS.
Journal ArticleDOI
Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.
TL;DR: Use of clozapine blood levels as a predictor for treatment response in treatment-refractory schizophrenic patients appears worthwhile, since the measurement's sensitivity for response was 64% and the specificity for nonresponse was 78%.
Journal ArticleDOI
Side Effects of Corticosteroid Therapy: Psychiatric Aspects
TL;DR: While dosage may be correlated to the risk of developing mental disturbances, neither dosage nor duration of treatment seems to affect the time of onset, duration, severity, or type of mental disturbances.
Journal ArticleDOI
Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder
Les Barrickman,Paul J. Perry,A.J. Allen,Samuel Kuperman,Stephan Arndt,Kenneth J. Herrmann,Elizabeth Schumacher +6 more
TL;DR: In this double-blind, crossover trial, bupropion and methylphenidate were both effective and did not differ in their overall efficacy as treatments for ADHD.
Journal ArticleDOI
Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.
Victoria S. Lim,Richard L. DeGowin,Donald C. Zavala,Peter T. Kirchner,Robert I. Abels,Paul J. Perry,Jerry Fangman +6 more
TL;DR: Recombinant human erythropoietin is effective and safe in ameliorating the anemia of pre-dialysis patients and dose-dependent rise in hematocrit is shown in subjects who received active r-HuEPO.